 |
|
Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study
Lingkun Kong, MD, PhD;
Helen A. Mintz-Hittner, MD;
Rebecca L. Penland, MS;
Francis L. Kretzer, PhD;
Patricia Chévez-Barrios, MD
Arch Ophthalmol. 2008;126(8):1161-1163.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Overexpression of vascular endothelial growth factor (VEGF) appears important in the pathogenesis of retinopathy of prematurity (ROP). Bevacizumab (Avastin; Genentech, Inc, South San Francisco, California) is a recombinant humanized monoclonal IgG1 antibody. It binds to and inhibits the biological activity of human VEGF.1 It has been estimated that more than 10 000 patients worldwide have been treated with intravitreous bevacizumab.2 We report results of a study in postmortem eyes with intravitreous bevacizumab treatment for zone 1, stage 2+ ROP in an extremely low-birth-weight infant.
Report of a Case
The protocol was approved by the institutional review board for the use of intravitreous injections of bevacizumab vs conventional laser therapy for the treatment of vision-threatening ROP.
A Hispanic boy delivered at 22 weeks' gestation weighing 350 g had hypoxia at birth with development of many multisystem complications . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Retinopathy of Prematurity: Clinical Insights from Molecular Studies
Heidary et al.
NeoReviews 2009;10:e550-e557.
ABSTRACT
| FULL TEXT
Retinopathy of Prematurity: Recent Developments
Fleck and McIntosh
NeoReviews 2009;10:e20-e30.
ABSTRACT
| FULL TEXT
|
